Drugs that contain Odevixibat

1. Drug name - BYLVAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416 ALBIREO Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(24 days ago)

US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

IN248635B ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia
Sep, 2022

(24 days ago)

IN200400539P1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia
Sep, 2022

(24 days ago)

EP1427423B9 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(24 days ago)

EP1427423A1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(24 days ago)

EP1427423B1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(24 days ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease Nov, 2031

(9 years from now)

US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.2MG CAPSULE, PELLETS;ORAL Prescription
0.6MG CAPSULE, PELLETS;ORAL Prescription
0.4MG CAPSULE;ORAL Prescription
1.2MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.